Deep Vein Thrombosis

Clinical Trial Finder

Many patients with deep vein thrombosis are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Pain Management Following Total Hip Arthroplasty

Conditions:   Postoperative Pain Intensity;   Rescue Pain Requirements
Intervention:   Drug: ropivacaine + ketorolac + adrenaline
Sponsor:   Örebro University, Sweden
Recruiting - verified October 2015

Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.

Conditions:   Deep Vein Thrombosis;   Chronic Portal Vein Thrombosis
Intervention:   Drug: Xarelto
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified September 2015

Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center

Conditions:   Cancer;   Deep-vein Thrombosis of the Lower and Upper Extremities;   Pulmonary Embolism;   Non-valvular Atrial Fibrillation
Intervention:   Other: Retrospective Chart Review
Sponsors:   M.D. Anderson Cancer Center;   Janssen Scientific Affairs, LLC
Recruiting - verified September 2015

PROphylaxis in NOn Major Orthopaedic Surgery

Condition:   Non-major Orthopaedic Surgery
Interventions:   Drug: Rivaroxaban;   Drug: Enoxaparin
Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Bayer
Not yet recruiting - verified September 2015

Predicting the Safety and Effectiveness of Inferior Vena Cava Filters

Condition:   Pulmonary Embolism
Intervention:   Device: IVC Filter
Sponsors:   New England Research Institutes;   IVC Filter Study Group Foundation (IDE Sponsor);   ALN Implants Chirurgicaux;   B. Braun Interventional Systems, Inc;   Bard Peripheral Vascular, Inc;   Cook;   Cordis Corporation;   Volcano Corporation;   Rex Medical
Not yet recruiting - verified October 2015

Thoracic Surgery Extended Low-Molecular Weight Heparin VTE Prophylaxis--Pilot Trial

Conditions:   Venous Thromboembolism;   Lung Neoplasms;   Pulmonary Embolism
Interventions:   Drug: LMWH: Dalteparin;   Other: Placebo
Sponsors:   McMaster University;   University Health Network, Toronto;   Credit Valley Hospital
Recruiting - verified September 2015

An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia

Conditions:   Sepsis;   Severe Sepsis
Sponsors:   University of Oxford;   National Institute of Allergy and Infectious Diseases (NIAID);   FHI 360;   Social & Scientific Systems Inc.
Recruiting - verified October 2015

Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation

Conditions:   Atrial Fibrillation;   Cardioembolic Events;   Oral Anticoagulation
Intervention:   Drug: Dabigatran
Sponsors:   Georg Nickenig;   Boehringer Ingelheim
Recruiting - verified October 2015

Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study

Condition:   Hip Fractures
Sponsor:   Population Health Research Institute
Completed - verified October 2015

The SENTRY Clinical Study

Conditions:   Pulmonary Embolism;   Deep Vein Thrombosis
Intervention:   Device: SENTRY IVC Filter
Sponsor:   Novate Medical
Recruiting - verified October 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified October 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified September 2015

Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery

Condition:   Anticoagulation
Intervention:   Drug: Apixaban
Sponsors:   Bristol-Myers Squibb;   Pfizer
Recruiting - verified July 2015

The Ideal Deep Venous Thrombosis (DVT) Study

Condition:   Postthrombotic Syndrome
Interventions:   Device: Individually tailored duration of elastic compression therapy;   Device: Elastic compression therapy with a standard duration of 24 months
Sponsors:   Maastricht University Medical Center;   ZonMw: The Netherlands Organisation for Health Research and Development
Active, not recruiting - verified July 2015

Post-authorization Safety Study of Etoricoxib and Other Anti-inflammatory Therapies in European Patients With Ankylosing Spondylitis (MK-0663-163)

Condition:   Ankylosing Spondylitis
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified September 2015

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

Conditions:   Deep Vein Thrombosis;   Venous Thrombosis;   Postphlebitic Syndrome;   Venous Thromboembolism;   Post Thrombotic Syndrome
Intervention:   Drug: Recombinant tissue plasminogen activator (rt-PA)
Sponsors:   Washington University School of Medicine;   McMaster University;   Ontario Clinical Oncology Group (OCOG);   National Heart, Lung, and Blood Institute (NHLBI);   BSN Medical Inc;   Genentech, Inc.;   Medtronic - MITG;   Boston Scientific Corporation;   Mid America Heart Institute;   Society of Interventional Radiology Foundation;   Massachusetts General Hospital
Active, not recruiting - verified October 2015

Low-Dose rtPA to Treat Blood Clots in Major Arm or Neck Veins

Condition:   Thrombosis
Intervention:   Procedure: Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)
Sponsor:   National Institutes of Health Clinical Center (CC)
Completed - verified December 2007

Get CardioSmart

You're Invited